{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 63 of 169', 'be documented on the trial medication inventory log and in the IWRS. Following', 'reconciliation, the trial kit cartons from used kits may be discarded.', 'All unused IMP supplied by the CMO on behalf of LEO will be returned to the CMO. IMP', 'may be returned from the trial site either to the CMO directly or via the LEO Pharma A/S', 'affiliate or CRO responsible for the running of the clinical trial. The IMP returned to the CMO', 'will be reconciled with the individual drug accountability forms.', 'For more information about IMP accountability, please refer to the IMP manual.', 'Where home-use is appropriate, the following apply:', 'Subjects will only attend trial visits every 4 weeks, i.e., in weeks where', 'efficacy and safety assessments are scheduled (Section 9.2). At these trial', 'visits, subjects will be provided with IMP to be administered at home at the', 'next dosing interval.', 'Subjects will be provided with sharps bins for used syringes. Filled sharps bins', 'will be returned to the trial site.', 'Subjects will return trial kit cartons, and any unused IMP at each trial visit.', 'Unused IMP returned by the subjects to the trial site can be stored at room', 'temperature and must be stored separately from non-allocated IMP.', 'The trial medication inventory log will document all IMP handed out to and', 'returned by each subject.', '9.9.4 Trial product destruction', 'Unused IMP(s) as well as used syringes returned to the CMO will be destroyed by the CMO', 'according to approved procedures and/or local requirements.', '9.9.5 Treatment compliance', 'IMP injections will be performed by site staff who will also keep the accountability records', 'up to date. Any non-compliance and the reason for it must be recorded in the eCRF.', 'Where home-use is appropriate, the following apply:', 'Subjects will record date and injection site for each administration in a log of drug', 'administration; these data will then be transcribed into the eCRF by site staff at the next trial', 'visit. If a subject is found to be non-compliant, the investigator should remind the subject of', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 64 of 169', 'the importance of following the treatment instructions including taking the IMP as prescribed.', 'Any non-compliance and the reason for it must be recorded in the eCRF.', 'Where tralokinumab is administered by the subject at the trial site (Section 9.2), the site staff', 'will record compliance data in the eCRF.', '9.10 Provision for subject care following trial completion', 'In order to ensure appropriate treatment of the subjects after they have completed the trial, the', \"subjects will be treated at the investigator's discretion or referred to other physician(s)\", 'according to standard practice. Subjects who qualify for the long-term extension trial (see', 'Section 7.1) may be offered participation.', '9.11 Reporting product complaints', 'Any defects or issues with the IMP as well as any device deficiency (including malfunctions,', 'use errors, and inadequate labelling) must be reported to Global Pharmacovigilance, LEO on', 'the trial-specific (paper) Complaint Form within 3 days of first knowledge.', 'Critical complaints (defined as any issue, defect, or device deficiency that has or potentially', 'could have a serious impact for the subject [e.g., SAE or large particles in the syringe]) must', 'be reported to Global Pharmacovigilance, LEO within 24 hours.', 'Complaint forms should contain a detailed description of the defect, issue, or device', 'deficiency, including whether it led to an AE. (S)AEs which occur due to a defect or issue', 'with the IMP or due to a device deficiency will be reported by the investigator as described in', 'Sections 11.2 and 11.3.', 'Refer to the IMP manual for information on how to update the kit status in the IWRS.', 'During the investigation of the product complaint, the device must be stored at labelled', 'conditions unless otherwise instructed; the trial site will be notified whether the device needs', 'to be returned for further investigation or may be destroyed.', 'Global Pharmacovigilance, LEO contact information for reporting product complaints:', 'Fax number: +45 7226 3287', 'E-mail address: drug.safety@leo-pharma.com', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}